Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins

被引:107
|
作者
Short, SM
Derrien, A
Narsimhan, RP
Lawler, J
Ingber, DE
Zetter, BR [1 ]
机构
[1] Harvard Univ, Sch Med, Vasc Biol Program, Childrens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[4] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
来源
JOURNAL OF CELL BIOLOGY | 2005年 / 168卷 / 04期
关键词
D O I
10.1083/jcb.200407060
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The anti-angiogenic effect of thrombospondin-1 has been shown to be mediated through binding of the type-1 repeat (TSR) domain to the CD36 transmembrane receptor. We now report that the TSR domain can inhibit VEGF-induced migration in human umbilical vein endothelial cells (HUVEC), cells that lack CD36. Moreover, we identified beta(1) integrins as a critical receptor in TSR-mediated inhibition of migration in HUVEC. Using pharmacological inhibitors of downstream VEGF receptor effectors, we found that phosphoinositide 3-kinase (PI3k) was essential for TSR-mediated inhibition of HUVEC migration, but that neither PLCgamma nor Akt was necessary for this response. Furthermore, beta1 integrins were critical for TSR-mediated inhibition of microvascular endothelial cells, cells that express CD36. Together, our results indicate that P, integrins mediate the anti-migratory effects of TSR through a PI3k-dependent mechanism.
引用
收藏
页码:643 / 653
页数:11
相关论文
共 50 条
  • [1] Inhibition of endothelial-cell migration by thrombospondin-1 type-1 repeats is mediated by beta(1)-integrins (vol 168, pg 643, 2005)
    Short, SM
    Derrien, A
    Narsimhan, RP
    Lawler, J
    Ingber, DE
    Zetter, BR
    JOURNAL OF CELL BIOLOGY, 2005, 169 (03): : 541 - 541
  • [2] Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats
    Iruela-Arispe, ML
    Lombardo, M
    Krutzsch, HC
    Lawler, J
    Roberts, DD
    CIRCULATION, 1999, 100 (13) : 1423 - 1431
  • [3] Alternative Chemistries for the Synthesis of Thrombospondin-1 Type 1 Repeats
    Tiefenbrunn, Theresa K.
    Blanco-Canosa, Juan
    Dawson, Philip E.
    BIOPOLYMERS, 2010, 94 (04) : 405 - 413
  • [4] THE TYPE-1 REPEATS OF THROMBOSPONDIN-1 ACTIVATE LATENT TRANSFORMING GROWTH-FACTOR-BETA
    SCHULTZCHERRY, S
    LAWLER, J
    MURPHYULLRICH, JE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (43) : 26783 - 26788
  • [5] Endothelial cell mitogenesis induced by LPA: Inhibition by thrombospondin-1 and thrombospondin-2
    Panetti, TS
    Chen, H
    Misenheimer, TM
    Getzler, SB
    Mosher, DF
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 129 (02): : 208 - 216
  • [6] Overexpression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of TGF-[betal].
    Yee, KO
    Streit, M
    Hawighorst, T
    Detmar, M
    Lawler, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6145S - 6145S
  • [7] Thrombospondin-1 and neural crest cell migration
    Tucker, RP
    Hagios, C
    Chiquet-Ehrismann, R
    Lawler, J
    Hall, RJ
    Erickson, CA
    DEVELOPMENTAL DYNAMICS, 1999, 214 (04) : 312 - 322
  • [8] Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1
    Calzada, MJ
    Annis, DS
    Zeng, BX
    Marcinkiewicz, C
    Banas, B
    Lawler, J
    Mosher, DF
    Roberts, DD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (40) : 41734 - 41743
  • [9] Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β
    Yee, KO
    Streit, M
    Hawighorst, T
    Detmar, M
    Lawler, J
    AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (02): : 541 - 552
  • [10] Aden-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin
    Zhang, Xuefeng
    Xu, Jianfeng
    Lawler, Jack
    Terwilliger, Ernest
    Parangi, Sareh
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3968 - 3976